Eli Lilly Stock News

The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.

Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts s

A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many W

Healthcare's impact on the economy cannot be overstated. According to the American Medical Association, the U.S. spends more than $4 trillion a year on healthcare, which works out to nearly $13,000 pe

Reaching the trillion-dollar market cap is a testament to any company's international influence, massive customer base and brand power. Indeed, being considered a peer of global behemoths like Microso

Eli Lilly (LLY) reachead $761.98 at the closing of the latest trading day, reflecting a +0.63% change compared to its last close.

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

Eli Lilly wowed patients and investors with its top-performing weight loss drugs. The big pharma company's stock has climbed in the triple digits over the past year thanks to its revenue growth.

Eli Lilly's weight loss drugs are generating billions of dollars in revenue. The company continues to develop candidates that may result in even better products.

Novo Nordisk and Eli Lilly make medicines that target GLP-1, which figures in a number of ailments. A new study found that a similar drug could help treat Parkinson's.

People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, accord

Eli Lilly is having trouble keeping up with the demand for Zepbound. This medicine could go on to break sales records.

We're at a crossroads in this current market. Tech and growth stocks continue to soar while undervalued stocks lag.

A Type 2 diabetes medication called lixisenatide appeared to slow the progression of Parkinson's disease symptoms in a small, mid-stage trial funded by the French Ministry of Health and others, the Ne